Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
Por:
Tahara, M, Greil, R, Rischin, D, Harrington, KJ, Burtness, B, de Castro, G, Psyrri, A, Braña, I, Neupane, P, Bratland, A, Fuereder, T, Hughes, BGM, Mesía, R, Ngamphaiboon, N, Rordorf, T, Ishak, WZW, Lin, JX, Gumuscu, B, Lerman, N and Soulières, D
Publicada:
15 may 2025
Ahead of Print:
1 abr 2025
Resumen:
Background: Pembrolizumab monotherapy and pembrolizumab-chemotherapy demonstrated superior overall survival (OS) versus cetuximab-chemotherapy (EXTREME) in the primary analysis of the phase III KEYNOTE-048 study of recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the first-line setting. We report updated data with 5 years of follow-up. Methods: Adults with previously untreated R/M HNSCC incurable by local therapy were randomly assigned 1:1:1 to pembrolizumab, pembrolizumab plus chemotherapy, or EXTREME. The primary endpoints were OS and progression-free survival (PFS). Results: Overall, 882 participants were assigned to pembrolizumab, pembrolizumab-chemotherapy, or EXTREME. Median study follow-up was 69.2 months (pembrolizumab) and 68.6 months (pembrolizumab-chemotherapy). Median OS remained longer for pembrolizumab versus EXTREME in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) >= 20 (HR, 0.61; 95 % CI, 0.46-0.81) and CPS >= 1 populations (HR, 0.74; 95 % CI, 0.61-0.89), and similar in the total population (HR, 0.82; 95 % CI, 0.69-0.97). Pembrolizumab-chemotherapy prolonged median OS in the PD-L1 CPS >= 20 (HR, 0.63; 95 % CI, 0.47-0.84), CPS >= 1 (HR, 0.65; 95 % CI, 0.53-0.79), and total (HR, 0.72; 95 % CI, 0.60-0.86) populations. The 5-year OS rate in the total population was 14.4 % for pembrolizumab versus 6.5 % for EXTREME and 16.0 % for pembrolizumab-chemotherapy versus 5.2 % for EXTREME. There was no clinically meaningful difference in PFS among pembrolizumab, pembrolizumab-chemotherapy, or EXTREME groups in any populations. Conclusions: These 5-year follow-up results support the use of pembrolizumab and pembrolizumab-chemotherapy as first-line standards of care for R/M HNSCC. Clinical Trial Information: NCT02358031. Prior Presentation: Presented at the European Society for Medical Oncology Congress, September 9-13, 2022.
Filiaciones:
Tahara, M:
Natl Canc Ctr Hosp East, 6-5-1 Kashiwanoha, Chiba, Kashiwa 2778577, Japan
Greil, R:
Paracelsus Med Univ Salzburg, Salzburg Canc Res Inst, Ctr Clin Canc & Immunol Trials, Canc Cluster Salzburg, Salzburg, Austria
Rischin, D:
Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
Univ Melbourne, Melbourne, Vic, Australia
Harrington, KJ:
Inst Canc Res, London, England
Burtness, B:
Yale Sch Med, New Haven, CT USA
de Castro, G:
Inst Canc Sao Paulo ICESP, Sao Paulo, Brazil
Psyrri, A:
Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Athens, Greece
Braña, I:
Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain
Neupane, P:
Univ Kansas, Med Ctr, Kansas City, KS USA
Bratland, A:
Oslo Univ Hosp, Oslo, Norway
Hughes, BGM:
Univ Queensland, Royal Brisbane & Womens Hosp, Herston, Qld, Australia
Ngamphaiboon, N:
Mahidol Univ, Ramathibodi Hosp, Ratchatewi, Bangkok, Thailand
Rordorf, T:
Univ Hosp, Zurich, Switzerland
Ishak, WZW:
Univ Malaya, Fac Med, Dept Clin Oncol, Kuala Lumpur, Malaysia
Lin, JX:
Merck & Co Inc, Rahway, NJ USA
Gumuscu, B:
Merck & Co Inc, Rahway, NJ USA
Lerman, N:
Merck & Co Inc, Rahway, NJ USA
Soulières, D:
Univ Montreal, Ctr Hosp Univ Montreal, Montreal, PQ, Canada
IGTP, Catalan Inst Oncol, Med Oncol Dept, B ARGO,CARE Program, Badalona, Spain
|